In 1957, Salmon and Daughaday observed that although normal serum or serum from hypophysectomized animals treated with growth hormone stimulated the in vitro uptake of 35SO4 by cartilage, growth hormone itself was completely inactive in this respect (1) . They postulated that there was a substance in serum stimulated by growth hormone, but distinct from it, that mediated the skeletal effects of growth hormone. This "sulfation factor" also stimulates the incorporation of thymidine into DNA (2) , uridine into RNA (3) , and the conversion of proline to hydroxyproline (4) in cartilage. Purified preparations of "sulfation factor" exhibit insulin-like effects in at least four different bioassay systems: incorporation of amino acids into rat diaphragm (5) , glucose degradation by epididymal fat pads (6) , antilipolytic action in epinephrine-stimulated epididymal fat pads (7) , and stimulation of protein synthesis and cell replication in HeLa cells (8) . Van Wyk et al. found that a substantial portion of the sulfation factor activity in human plasma could be attributed to a neutral peptide with a molecular weight of about 7000 (9, 10) . Sulfation factor and thymidine factor activities could not be dissociated after purification about 25,000-fold. Hall and Uthne were unable to dissociate sulfation factor activity from nonimmunoreactive insulin-like activity during similar purification procedures (6) . Because of their chemical and biological similarities, it was proposed that sulfation factor, thymidine factor, and the acid-ethanol soluble component of nonsuppressible insulin-like activity in serum described by Jakob et al. (11) [125I]Insulin, with a specific activity of 120-225 pCi/Mg, was prepared by the method of Cuatrecasas (15) . Fat cells were prepared from rat epididymal fat pads by the method of Rodbell (17) . Chondrocytes were prepared by the method of Garland et al. (18) from pelvic leaflets of 12-day fetal chickens. Rat liver membranes were prepared by the method of Cuatrecasas (19 (Fig. 1) . The apparent ratio of somatomedin to insulin in this * One unit of somatomedin is defined as the amount of sulfation factor activity in one ml of a standard reference plasma. (Fig. 2) . The presence of lower-affinity, higher-capacity receptors was suggested by the change in slope at the higher dosages. Accurate calculations of K.AS8, for somatomedin cannot be made, however, until it becomes possible to transpose biological units into molar concentrations. membranes by somatomedin was also closely similar to that of insulin (Fig. 3) . In this instance, the ratio appears to be 200 /iunits of insulin per unit of somatomedin.
Isolated chondrocytes differed from adipocytes and liver
cell membranes in that a smaller percentage of [I2fIlinsulin was specifically bound, and the curves were not parallel over the range of dosages studied. Somatomedin was much more effective than even large amounts of unlabeled insulin in displacing ['2DI]insulin (Fig. 4) Since the material used in this study was not absolutely pure, it is possible that the effects seen may be attributable to more than one molecular species that are very similar in size and charge. This 1 unit of somatomedin is in our hands equivalent to about 20 ,uunits of insulin, whereas in a rat rib cartilage assay for sulfation and thymidine factor activities, 1 unit of somatomedin is equivalent to 30 milliunits of insulin (unpublished results).
Although the exquisite sensitivity of the cartilage receptor to somatomedin is consonant with the original tissue-specific, growth-promoting role originally postulated by Daughaday, both fat and liver receptors are responsive to concentrations of somatomedin that are well below the concentrations normally found in serum. These findings further sharpen the paradox that Froesch (20) has attempted to deal with: the existence of large amounts of insulin-like activity in the serum of animals dying in diabetic coma. It is possible that factors operating in vivo, but not in vitro, limit the interaction of somatomedin with receptors in nonskeletal tissue.
The competitive binding of somatomedin and insulin at low concentrations implies that at least some segments of the somatomedin molecule must be very similar to the receptor recognition sites on the insulin molecule. Impressive structural homologies have recently been demonstrated by Frazier et al. (21) between nerve growth factor and insulin, and it was postulated (21) that nerve growth factor was derived from the same ancestral protein as was insulin.
Nerve growth factor, somatomedin, and insulin all share the capacity to stimulate in their respective target tissues the set of biochemical reactions characteristic of rapid cellular proliferation. These reactions have been collectively described by Hershko et al. (22) as a positive "pleiotypic responses of nerve growth factor and other tissue-specific growth factors such as erythropoietin (23) , epidermal growth factor (24) , and Multiplication Stimulating Activity (13) can be related to competition with insulin for common membrane binding sites. If so, it can be predicted that their respective binding affinities in various tissues, as in the case of somatomedin, will reflect their tissue specificities. It may indeed be possible that there exists a family of biologically active peptides homologous to insulin that differ in their target organ specificities and hormonal control mechanisms.
